Improving Compliance With Antitrust Measures Through Commercial Policies

Коммерческие политики как форма антимонопольного комплаенса (на примере фармацевтических компаний)

Avdasheva, Svetlana (Авдашева, Светлана) (), Khomik, Olesya (Хомик, Олеся) () and Yusupova, Gyuzel (Юсупова, Гюзель) ()
Additional contact information
Avdasheva, Svetlana (Авдашева, Светлана): National Research University Higher School of Economics
Khomik, Olesya (Хомик, Олеся): National Research University Higher School of Economics
Yusupova, Gyuzel (Юсупова, Гюзель): National Research University Higher School of Economics

Ekonomicheskaya Politika / Economic Policy, 2024, vol. 19, issue 2, 6-35

Abstract: Commercial policies for major market participants were introduced in Russia about a decade ago in order to improve compliance with antitrust provisions and as a partial substitute for them. Experts were initially rather sceptical about this move because it was a departure from prevailing international practices and also imposed additional regulatory burdens on companies. This article examines whether commercial policies have been an effective way to improve antitrust compliance by Russia’s pharmaceutical companies, reduce erroneous accusations, and drive down the costs of antitrust enforcement for both the antitrust authorities and market players. Analysis of the commercial policies of several large pharmaceutical companies indicates that their rules are meant to address the abuse of market dominance in the sector which has been alleged by the Federal Antimonopoly Service of the Russian Federation (FAS). Inasmuch as a refusal to supply counts as an infringement of Russia’s legislation on competition and also in view of particular aspects of competition in the Russian pharmaceutical markets, such commercial policies have great potential, first, to diminish erroneous accusations and, second, to reduce the costs of enforcing the legislation on competition. The authors conclude that introducing commercial policies has been beneficial for both consumers (as represented by the FAS) and the pharmaceutical companies.

Keywords: commercial policies; competition; pharmaceutical markets; distributors (search for similar items in EconPapers)
JEL-codes: K21 L42 L52 L53 L65 (search for similar items in EconPapers)
Date: 2024
References: Add references at CitEc
Citations:

Downloads: (external link)
https://repec.ranepa.ru/rnp/ecopol/ec2405.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:rnp:ecopol:ec2405

DOI: 10.18288/1994-5124-2024-2-6-35

Access Statistics for this article

Ekonomicheskaya Politika / Economic Policy is currently edited by Sergey Drobyshevsky

More articles in Ekonomicheskaya Politika / Economic Policy from Russian Presidential Academy of National Economy and Public Administration Contact information at EDIRC.
Bibliographic data for series maintained by RANEPA maintainer ().